Innovative aspects and competitive advantages
1. Human Protein-based Modular Cell Engineering Platform
DNAmic Biosystems has developed a modular cell bioengineering platform, designed from optimized human proteins. This innovative approach eliminates dependence on viral vectors or synthetic nanoparticles, significantly reducing the toxicity and immunogenicity problems that constrain conventional delivery systems. The ability to modulate its structure allows the platform to adapt to different therapeutic needs, providing a universal solution for cell reprogramming within the body.
2. In Vivo Cellular Reprogramming Directed
Unlike traditional cell therapies, which require the extraction, manipulation and reintroduction of cells into the body, DNAmic technology allows cell reprogramming directly within the body. This eliminates the need for invasive procedures and allows treatment to be more accessible, faster and safer for the patient. With this approach, cells can be modified to restore their function, eliminate pathologies or give them new therapeutic capabilities without permanently altering the DNA.
3. Superior Therapeutic Load Capacity
Another disruptive development of this platform is its therapeutic load capacity. DNAmic has designed a system that can encapsulate more than 12,000 RNA or DNA bases, far exceeding the capabilities of current delivery systems. This capability allows the administration of messenger RNA, gene editing systems, therapeutic proteins and even combinations of different molecules in a single formulation.
4. Specific Cell Address and Improved Affinity
The DNAmic platform incorporates a high-precision cellular addressing mechanism, based on human proteins optimized to interact exclusively with target cells. The envelope of nanoparticles has been redesigned to eliminate their non-target cell interaction and redirect them with an affinity equal to or even greater than that of an antibody for its specific receptor. This ensures that therapy is delivered only to the cells that require it, improving efficacy and dramatically reducing side effects associated with systemic drug administration.
5. Virus-free and Non-integrative Technology
The system developed by DNAmic does not use viral vectors or permanently alter the genome of cells. This non-integrative technology allows transient modification of cell function without the risk of mutagenesis, oncogenic activation or adverse immunological responses. By avoiding irreversible genetic manipulation, a more secure and flexible platform is achieved, with applications in precision therapies that can be dynamically adapted to the patient’s needs.
6. Versatile Therapeutic Applications
The potential of this technology extends to various therapeutic areas. In the field of immunotherapy, DNAmic has developed CAR-T therapies in vivo, allowing direct reprogramming of T lymphocytes within the patient to attack tumors more effectively. In addition, work is being done on guided cell engineering in macrophages, designing strategies to teach them how to detect and eliminate viruses before they even infect human cells. The first application of this approach is being tested on HIV, with the possibility of spreading to other viral infections. Beyond immunotherapy, this platform opens up new opportunities to treat neurodegenerative, autoimmune and metabolic diseases such as diabetes, offering solutions where current treatments have proven insufficient.
7. High Scalability and Ease of Production
One of the challenges in the development of advanced therapies is their large-scale feasibility. The DNAmic platform is designed with an industrial scalability approach, using reprogrammed human proteins, capable of being produced by existing manufacturing processes in the biopharmaceutical industry. This feature reduces production costs and accelerates the arrival of technology on the market, facilitating its adoption in clinical settings.
8. Safety and Side Effect Reduction
Based on human proteins, DNAmic has designed a platform with a superior security profile. In addition, the precision of cell targeting minimizes systemic toxicity, while the ability to temporarily modify cell function avoids the long-term risks associated with genetic manipulation.
9. Solid Intellectual Property
DNAmic has protected its technology through two key patents, one for the Core-Cargo and one for the Envelope, consolidating its position in the field of guided cell engineering. This intellectual property supports the platform’s commercial viability and strengthens opportunities for partnerships with academic institutions, laboratories and the pharmaceutical industry.
10. Business Model Based on Strategic Collaborations
DNAmic’s business model is based on collaboration with research laboratories, academic centers and biopharmaceutical companies, establishing co-development, licensing and marketing agreements. These partnerships accelerate the preclinical and clinical validation of technology, facilitating its access to patients and maximizing its impact on precision medicine.
Building the Future of Medicine
Our guided cell engineering platform has the potential to reprogram any cell in the body with unprecedented precision, offering a completely innovative approach to treating disease from its root. This development represents a transformation in the way we understand and apply biotechnology in the clinical field, opening up new possibilities for treating complex diseases that had no effective solution until now.
